Biosante Pharmaceuticals Inc (NASDAQ:BPAX), InterMune, Inc. (NASDAQ:ITMN), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) and PDL BioPharma Inc. (NASDAQ:PDLI) all closed above the breakeven line.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) advanced in final trading hours to end the day up 4.30% after revealing safety findings from the phase II BELIEF study on belinostat.

Theravance Inc (NASDAQ:THRX) surged 3.98% after Cowen launched coverage on the stock with an outperform rating.

Athersys, Inc. (NASDAQ:ATHX) and Cell Therapeutics Inc (NASDAQ:CTIC) both traded higher after a Seeking Alpha article consider them as one of the most underappreciated Cell therapy stocks.

Biogen Idec Inc. (NASDAQ:BIIB) increased $3.93 in price on Tuesday, extending gains after results.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded 1.85% higher after the company declared completion of public offering.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) turned green after Decision Resources predicted that four agents will roll out for soft tissue sarcoma between now and 2018 – palifosfamide (Ziopharm’s Zymaphos), eribulin (Eisai’s Halaven), crizotinib (Pfizer’s Xalkori) and Threshold Pharmaceuticals’ TH-302.

Amgen, Inc. (NASDAQ:AMGN) was the most active stock in the biotechnology industry, adding 1.17% after a Motley Fool article titled “Three Takeaways From This Biotech Giant’s 2012 Earnings”.

Gilead Sciences, Inc. (NASDAQ:GILD) rallied after Forbes reported the company is challenging a crucial bit of FDA decision making.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gained after providing FY 2013 outlook that met expectations but, later in after-market trading, the stock faced a fall on quarterly loss.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) advanced 1.01% and Celgene Corporation

(NASDAQ:CELG) added 0.25% while NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) was down after news of their participation in the 15Th Annual BIO CEO & Investor Conference scheduled to be held February 11–12, 2013 in NYC.

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) hit new high.

Exelixis, Inc. (NASDAQ:EXEL), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and NuPathe Inc (NASDAQ:PATH) each edged up while DARA Biosciences Inc (NASDAQ:DARA) and Hemispherx BioPharma, Inc (NYSEAMEX:HEB) ended with no change on Tuesday.

On the flip side, Anacor Pharmaceuticals Inc (NASDAQ:ANAC) was the biggest loser after the company released results from study of potential nail fungus treatment. The news sent its share 20.5% down to suffer an all-time low hit.

Celsion Corporation (NASDAQ:CLSN) tumbled 6.11% after a report revealed that most buy side investors are of a view that HEAT trial of Thermodox + Radio Frequency Ablation (RFA) in treating liver cancer will fail in meeting its primary efficacy endpoints.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) declined 5.71%, seemingly due to negative comments in an article titled “EnteroMedics’ Late Stage Treatment Takes on Obesity Epidemic”.

Sequenom, Inc. (NASDAQ:SQNM) lost 5.66% to $4.33, retreating from gains it recorded on Monday.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) declined 5.06%, facing second fall in a row.

Illumina, Inc.(NASDAQ:ILMN) fell after mixed outlook.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) extended fall after The Street analysts reaffirmed their sell rating on the stock.

ImmunoGen, Inc. (NASDAQ:IMGN) continued to decline after a downgraded to “Perform” from “Outperform” at Oppenheimer & Co.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was down after Officer M. Wood sold 47,000 shares of the company’s stock, valued at $2,571,000.00 at a price in a range of $54.81-55.00 on 1/22/13.

Medivation, Inc. (NASDAQ:MDVN), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), EXACT Sciences Corporation (NASDAQ:EXAS) and Galena Biopharma Inc (NASDAQ:GALE) each lost more than 2% while Dendreon Corporation (NASDAQ:DNDN), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) and Incyte Corporation (NASDAQ:INCY) all fell between 2 and 0.5 percent.